MRK – Merck & Co., Inc.
Merck & Company, Inc.MRK
$87.61Name : Merck & Company, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $218,830,798,848.00
EPSttm : 6.49
Merck & Company, Inc.
$87.61
1.34%$1.19Float Short %
1.11
Margin Of Safety %
29
Put/Call OI Ratio
0.72
EPS Next Q Diff
0.08
EPS Last/This Y
1.28
EPS This/Next Y
0.68
Price
87.58
Target Price
101.95
Analyst Recom
2
Performance Q
4.66
Relative Volume
0.74
Beta
0.35
Ticker: MRK
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | MRK | 84.16 | 0.74 | 0.52 | 703044 |
| 2025-09-09 | MRK | 84.65 | 0.74 | 0.26 | 712364 |
| 2025-09-10 | MRK | 84.1 | 0.74 | 1.25 | 716451 |
| 2025-09-11 | MRK | 85.26 | 0.74 | 1.00 | 724255 |
| 2025-09-12 | MRK | 82.84 | 0.76 | 0.11 | 737731 |
| 2025-09-15 | MRK | 81.04 | 0.77 | 0.71 | 722462 |
| 2025-09-16 | MRK | 81.12 | 0.76 | 0.47 | 731074 |
| 2025-09-17 | MRK | 81.14 | 0.73724872735883 | 1.3328809879224 | 733727 |
| 2025-09-18 | MRK | 81.54 | 0.76 | 1.10 | 748045 |
| 2025-09-19 | MRK | 81.45 | 0.75 | 1.08 | 754569 |
| 2025-09-22 | MRK | 80.4 | 0.77 | 0.89 | 610954 |
| 2025-09-23 | MRK | 79.96 | 0.78 | 0.61 | 632186 |
| 2025-09-24 | MRK | 79.65 | 0.78 | 0.46 | 645856 |
| 2025-09-25 | MRK | 77.62 | 0.76 | 0.78 | 668192 |
| 2025-09-26 | MRK | 78.54 | 0.74 | 0.88 | 685884 |
| 2025-09-29 | MRK | 78.58 | 0.76 | 0.58 | 678147 |
| 2025-09-30 | MRK | 83.9 | 0.75 | 0.35 | 690377 |
| 2025-10-01 | MRK | 90.11 | 0.75 | 0.38 | 718400 |
| 2025-10-02 | MRK | 89.49 | 0.76 | 0.63 | 747617 |
| 2025-10-03 | MRK | 89.18 | 0.76 | 0.43 | 770772 |
| 2025-10-06 | MRK | 88.8 | 0.74 | 0.22 | 740053 |
| 2025-10-07 | MRK | 87.61 | 0.72 | 0.53 | 757195 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | MRK | 84.09 | 50.7 | 8231.5 | 8.93 |
| 2025-09-09 | MRK | 84.62 | 50.7 | 8560.3 | 8.93 |
| 2025-09-10 | MRK | 84.04 | 50.7 | 8226.4 | 8.93 |
| 2025-09-11 | MRK | 85.15 | 50.7 | 8739.9 | 8.93 |
| 2025-09-12 | MRK | 82.83 | 50.7 | 7702.2 | 8.93 |
| 2025-09-15 | MRK | 81.05 | 50.7 | 8103.0 | 8.93 |
| 2025-09-16 | MRK | 81.09 | 50.7 | 8672.8 | 8.93 |
| 2025-09-17 | MRK | 81.14 | 50.7 | 8666.3 | 8.93 |
| 2025-09-18 | MRK | 81.54 | 50.7 | 8777.5 | 8.93 |
| 2025-09-19 | MRK | 81.49 | 50.8 | 8638.0 | 8.93 |
| 2025-09-22 | MRK | 80.40 | 50.8 | 8300.1 | 8.93 |
| 2025-09-23 | MRK | 79.95 | 50.8 | 8506.6 | 8.93 |
| 2025-09-24 | MRK | 79.65 | 50.8 | 8550.6 | 8.93 |
| 2025-09-25 | MRK | 77.60 | 50.8 | 7983.1 | 8.93 |
| 2025-09-26 | MRK | 78.56 | 50.8 | 8965.8 | 8.93 |
| 2025-09-29 | MRK | 78.56 | 50.8 | 8621.7 | 8.93 |
| 2025-09-30 | MRK | 83.93 | 50.8 | 10394.3 | 8.93 |
| 2025-10-01 | MRK | 90.12 | 50.8 | 10557.5 | 8.93 |
| 2025-10-02 | MRK | 89.44 | 50.8 | 8455.6 | 8.93 |
| 2025-10-03 | MRK | 89.17 | 50.8 | 8553.1 | 8.93 |
| 2025-10-06 | MRK | 88.79 | 50.4 | 8191.8 | 8.93 |
| 2025-10-07 | MRK | 87.58 | 50.4 | 8046.9 | 8.93 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | MRK | -0.17 | -0.99 | 1.02 |
| 2025-09-09 | MRK | -0.17 | -0.99 | 1.02 |
| 2025-09-10 | MRK | -0.17 | -0.99 | 1.02 |
| 2025-09-11 | MRK | -0.17 | -0.99 | 0.95 |
| 2025-09-12 | MRK | -0.17 | -0.99 | 0.95 |
| 2025-09-15 | MRK | -0.17 | -0.96 | 0.95 |
| 2025-09-16 | MRK | -0.17 | -0.96 | 0.95 |
| 2025-09-17 | MRK | -0.17 | -0.96 | 0.95 |
| 2025-09-18 | MRK | -0.17 | -0.96 | 0.95 |
| 2025-09-19 | MRK | -0.17 | -0.96 | 0.95 |
| 2025-09-22 | MRK | -0.17 | -0.94 | 0.95 |
| 2025-09-23 | MRK | -0.17 | -0.94 | 0.95 |
| 2025-09-24 | MRK | -0.17 | -0.94 | 0.95 |
| 2025-09-25 | MRK | -0.17 | -0.94 | 1.11 |
| 2025-09-26 | MRK | -0.17 | -0.94 | 1.11 |
| 2025-09-29 | MRK | -0.17 | -0.96 | 1.11 |
| 2025-09-30 | MRK | -0.17 | -0.96 | 1.11 |
| 2025-10-01 | MRK | -0.17 | -0.96 | 1.11 |
| 2025-10-02 | MRK | -0.17 | -0.96 | 1.11 |
| 2025-10-03 | MRK | -0.17 | -0.96 | 1.11 |
| 2025-10-06 | MRK | -0.17 | -0.60 | 1.11 |
| 2025-10-07 | MRK | -0.17 | -0.60 | 1.11 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.13
Avg. EPS Est. Current Quarter
2.37
Avg. EPS Est. Next Quarter
2.21
Insider Transactions
-0.17
Institutional Transactions
-0.6
Beta
0.35
Average Sales Estimate Current Quarter
17000
Average Sales Estimate Next Quarter
16262
Fair Value
113.03
Quality Score
97
Growth Score
84
Sentiment Score
93
Actual DrawDown %
34.9
Max Drawdown 5-Year %
-43.4
Target Price
101.95
P/E
13.51
Forward P/E
9.1
PEG
1.22
P/S
3.45
P/B
4.48
P/Free Cash Flow
14.86
EPS
6.49
Average EPS Est. Cur. Y
8.93
EPS Next Y. (Est.)
9.6
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
25.87
Relative Volume
0.74
Return on Equity vs Sector %
8.3
Return on Equity vs Industry %
-0.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
8046.9
Merck & Company, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading